<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02422706</url>
  </required_header>
  <id_info>
    <org_study_id>HELICOBACTER NEW TREATMENT</org_study_id>
    <nct_id>NCT02422706</nct_id>
  </id_info>
  <brief_title>Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori</brief_title>
  <official_title>Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sherief Abd-Elsalam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current Helicobacter Pylori infection preferred treatment involves; proton pump inhibitor&#xD;
      (PPI)-based triple or qudrable regimens. Omeprazole, Amoxicillin, and Clarithromycin is one&#xD;
      of a global standard care for confirmed H.pylori infection . Metronidazole (MTZ) is used&#xD;
      instead of Amoxicillin or Clarithromycin in cases of allergy or resistance .&#xD;
&#xD;
      However, a recent study based on the Maastricht III guidelines, indicated that treatment with&#xD;
      a PPI-based triple regimen as first-line therapy will fail in ~30% of patients on an&#xD;
      intention-to-treat (ITT) basis, and will fail in ~ 50 % of patients who treated with&#xD;
      PPI-based triple regimen with Metronidazole. This treatment resistance is also an issue&#xD;
      warranting the investigation of other agents. Helicobacter pylori infection has become&#xD;
      increasingly resistant to traditional first-line treatment regimens because of emerging&#xD;
      antibiotic resistance coupled with poor patient compliance with completing the treatment&#xD;
      course that decrease H. pylori eradication rates. So there is a considerable interest in&#xD;
      evaluating new antibiotic combinations and regimens .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori (H.pylori) is a small, Gram-negative spirochete inhabiting the mucous&#xD;
      layer overlying the gastric epithelial cells in humans. It is the most common prevalent&#xD;
      chronic human bacterial infection and the most common cause of gastritis worldwide;.&#xD;
      Furthermore, according to the World Health Organization, HP is classified as a type 1&#xD;
      carcinogen and is the primary cause of peptic ulcer disease, gastric carcinoma, and&#xD;
      mucosa-associated lymphoid tissue lymphomas .&#xD;
&#xD;
      Current Helicobacter Pylori infection preferred treatment involves; proton pump inhibitor&#xD;
      (PPI)-based triple or qudrable regimens.Omeprazole,Amoxicillin &amp;Clarithromycin is one of a&#xD;
      global standard care for confirmed H.pylori infection .Metronidazole (MTZ) is used instead of&#xD;
      Amoxicillin or Clarithromycin in cases of allergy or resistance .&#xD;
&#xD;
      However, a study by Rokkas , et al., 2008 based on the Maastricht III guidelines, indicated&#xD;
      that treatment with a PPI-based triple regimen as first-line therapy will fail in ~30% of&#xD;
      patients on an intention-to-treat (ITT) basis,and will fail in ~ 50 % of patients who treated&#xD;
      with PPI-based triple regimen with Metronidazole.This treatment resistance is also an issue&#xD;
      warranting the investigation of other agents . Helicobacter pylori infection has become&#xD;
      increasingly resistant to traditional first-line treatment regimens because of emerging&#xD;
      antibiotic resistance coupled with poor patient compliance with completing the treatment&#xD;
      course that decrease H. pylori eradication rates .So there is a considerable interest in&#xD;
      evaluating new antibiotic combinations and regimens.&#xD;
&#xD;
      Nitazoxanide (NTZ) is an antibiotic with microbiological characteristics similar to those of&#xD;
      Metronidazole which was sittled as a therapy for intestinal protozoa and helminthic&#xD;
      infection,and was studied as an additional therapy with Peg Interferon and Ribavirin for&#xD;
      chronic hepatitis C virus (HCV) .&#xD;
&#xD;
      In the last few years Nitazoxanide was evaluated as a single agent therapy for H. Pylori&#xD;
      infection showing controversed results.. However (NTZ) based regimens were recently studied&#xD;
      showing interesting results without the apparent problem of resistance as Metronidazole with&#xD;
      nearby cost.Moreover ;Levofloxacin,PPI,NTZ&amp;Doxycycline (LOAD) regimen with very good results&#xD;
      in H.pylori infection ~90% cure rate..But uptil now there are no actual similar reported&#xD;
      trials in Egypt.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>blinding was applied by using consecutively numbered envelopes that contained the treatment assignments</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with proven eradication of helicobacter</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of patients with proven eradication of helicobacter after 6 weeks</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Helicobacter-associated Gastritis</condition>
  <arm_group>
    <arm_group_label>group I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metronidazole(MTZ) 500mg twice daily ,Omeprazole 20 mg twice daily as (Proton Pump Inhibitor (PPI)&amp; Clarithromycin 500 mg twice daily .for 14 days .&#xD;
40 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitazoxanide(NTZ)500 mg twice daily ,PPI 20 mg twice daily &amp; Clarithromycin 500 mg twice daily for 14 days.&#xD;
40 patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levofloxacin 250 mg once daily,Omeprazole 40mg once daily(PPI),Nitazoxanide (NTZ) 500mg twice daily &amp; Doxicycline 100 mg once daily (LOND).&#xD;
40 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>Nitazoxanide based treatment regimens as a new treatment regimens for helicobacter pylori infection</description>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_label>Group III</arm_group_label>
    <other_name>Alenia,parazoxanide,Nitclean</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole(MTZ)</intervention_name>
    <description>Metronidazole 500 mg twice daily</description>
    <arm_group_label>group I</arm_group_label>
    <other_name>Flagyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Omeprazole 20 twice daily</description>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_label>group I</arm_group_label>
    <other_name>Omepak. Napizole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>KLacid twice daily</description>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_label>group I</arm_group_label>
    <other_name>KLacid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>Tavanic. Tavacin</description>
    <arm_group_label>Group III</arm_group_label>
    <other_name>Levofloxacin once daily</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxicycline</intervention_name>
    <description>Vibramycin 100 mg twice daily</description>
    <arm_group_label>Group III</arm_group_label>
    <other_name>vibramycin. Doxymycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consecutive patients with dyspeptic symptoms undergoing upper Gasto-intestinal tract&#xD;
             (GIT) endoscopy selecting HP infected patients to be recruited for the study.&#xD;
&#xD;
          -  Patients must have had Helicobacter Pylori - induced disease confirmed by endoscopy&#xD;
             and HP monoclonal stool antigen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous gastric or duedenal operations or malignancy.&#xD;
&#xD;
          2. Active GIT bleeding.&#xD;
&#xD;
          3. Pregnancy.&#xD;
&#xD;
          4. Previous treatment for HP.&#xD;
&#xD;
          5. Current use of Antiacids ( proton pump inhibitor ( PPI ), H2 receptor antagonist) ,&#xD;
             anticoagulant, or recent use of antibiotics (within 6 weeks).&#xD;
&#xD;
          6. Allergy to any medication included in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mona AH Shehata, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>liver dis dept</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherief Abd-Elsalam, Consultant</last_name>
    <role>Study Director</role>
    <affiliation>Division of Gastroenterology and Hepatology- Tanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raghda Talaat, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Microbiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huda Elmesseri, Specialist</last_name>
    <role>Study Chair</role>
    <affiliation>liver diseases dept.-Elmahalla hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tanta university hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherief Abd-Elsalam</last_name>
      <phone>00201000040794</phone>
      <email>Sherif_tropical@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2015</study_first_posted>
  <last_update_submitted>April 23, 2017</last_update_submitted>
  <last_update_submitted_qc>April 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sherief Abd-Elsalam</investigator_full_name>
    <investigator_title>Tanta university</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Nitazoxanide</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

